Genmab — Juli 2018

[JKY_VH]

Tak ilm Helge og bliv nu ikke alt for rastløs under din lange sommerferie

[transalp]

Jep go ferie.. godt børsen holder lukket i din sommerferie, så du ikk misser noget..:) og go weekend til alle..

[bikube]

Grunden til at vi fik et positivt luk var, at Danske løb tør. De havde kun 1000 aktier tilbage i auktionen, efter at ha
ve holdt kursen nede hele dagen. Danske og ABG har dagen igennem netto solgt flere, end de anonyme har har netto købt, og de har næsten været ene om at købe. så - bibob (10.28) der var nogen, der ville sælge.

[bibob]

Ja, det må være nogen der skal bruge penge til is. :-).

[bibob]

God ferie Helge. :-). Håber vi kan holde skansen.

[bibob]

Ser ud til at ADC terapierne er lidt i unåde. https://www.fiercebiotech.com/biotech/patient-death-prompts-fda-hold-mersana-s-lead-cancer-adc?mkt_tok=eyJpIjoiWldRM05qUTVaVFk0WW1FMyIsInQiOiJoWXJOZTBhNzhjNWdlXC9sU3FWeTJVNFwvbVUyalc4YVpDWm1JS2FleFhXZlJWcVY2Tk5TN3VaeFo3ek9HOHFyQVIydjZ3RlM3U09JTWY4NDdsVDlFdlhNUjhJQmJvQ01TaTRmdElCYWdEUkwyUk1Fc1lsaXdMWlFPSklhK25xVUVQIn0%3D&mrkid=41140432

[E_L]

Limo Chen, CD38-mediated immunosuppression as a mechanism of tumor cell
escape from PD-1/PD-L1 blockade http://cancerdiscovery.aacrjournals.org/content/candisc/early/2018/07/14/2159-8290.CD-17-1033.full.pdf

[E_L]

History

Received September 13, 2017
Revision received April 10, 2018
Accepted July 11, 2018
Published first July 16, 2018

[E_L]

is this his original article or an update, i am not sure

[Solsen]

The mechanism of immune resistance to anti-PD- L1/PD-1 therapy caused by CD38 provides an evident rationale for recruitment of cancer patients for clinical trials of anti-CD38 in combination with anti-PD-L1/PD-1 to prevent therapy resistance and further enhance anti-tumor efficacy.

[Solsen]

It looks like a new article to me.

[gentogen]

Der er fire forskellige:

[gentogen]

CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.
L Chen, LA Byers, S Ullrich, II Wistuba, XF Qin… - 2017 - ascopubs.org

[gentogen]

Targeting CD38 to improve anti-PD-1/CTLA-4 combination therapy in lung cancer.
L Chen, Y Li, X Yi, DL Gibbons - 2018 - ascopubs.org

[gentogen]

CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response
L Chen, L Diao, Y Yang, X Yi, J Rodriguez, Y Fan… - 2017 - AACR

[gentogen]

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li… - Cancer Discovery, 2018 - AACR

[gentogen]

Fra nummer to: Conclusions: Targeting CD38 improves the efficacy of anti-PD-1/CTLA-4 combination therapy in lung cancer. CD38 on tumor cells could potentially serve as a novel biomarker of resistance for immune checkpoint inhibition."

[gentogen]

tumor bearing mice treated with combined PD-1 and CTLA-4 blocking antibodies developed resistance through the up-regulation of CD38, and that targeting CD38 abolished the resistance in a manner dependent on B7-costimulation

[Legolas23]

Bliver spændende om BMS-studierne kommer op med resultater, som underbygger.

[Legolas23]

Hvad tænker du?